Looking back at 2025, it has been a year of significant growth and recognition for MarkerX. We not only officially obtained the “Biotechnology and Pharmaceutical Company” designation from the government, but our core technology, MyeloTrak, was also honored with the 22nd National Innovation Award. This recognition solidifies MarkerX’s leadership in the field of Multiple Myeloma monitoring and demonstrates that our MIT (Made in Taiwan) R&D capabilities are effectively addressing the most urgent clinical needs.
Over the past year, we achieved major breakthroughs in patent portfolios and AI screening technologies, supported by steady revenue from our specialized Proteomics research services. Having listened to diverse perspectives and received positive clinical feedback, we remain steadfast in our belief that true precision medicine must be patient-centric. We are grateful to all our partners for their support; in 2026, we will continue to transform technical innovation into hope for a better life.
2025 Annual Milestones
Operational Excellence & Honors
- National Innovation Award: Our core technology, MyeloTrak, received the “Enterprise Startup Award” at the 22nd National Innovation Awards, with its clinical value highly praised by experts.
- Government Certification: MarkerX successfully passed the rigorous review by the Ministry of Economic Affairs to be designated as a “Biotechnology and Pharmaceutical Company,” affirming our R&D strength and operational compliance.
- 5th Anniversary Milestone: Since our founding in 2020, MarkerX has successfully transitioned MIT R&D energy into tangible clinical monitoring value.
MyeloTrak: Clinical Progression & Global IP Strategy
- Global Patent Protection: Successfully filed a U.S. Provisional Patent Application, establishing an international IP moat for our Proteomics-based detection methods.
- Advancing Clinical Validation: Launched retrospective studies with multiple top-tier medical centers to verify clinical benefits in monitoring relapse risks for Multiple Myeloma patients post-transplantation.
- Academic Authority: Completed submissions to top-tier journals, letting the data speak for itself on a global stage.
AI Multi-Cancer Early Detection (MCED): Technical Breakthroughs
- AI Engine Upgrade: Delivered the second-generation MK II modeling engine, significantly enhancing the efficiency of processing large-scale Proteomics datasets.
- Enhanced Stability: Overcame “batch effects” through technical breakthroughs, reducing the coefficient of variation (CV) by over 28% to ensure highly stable and reliable results.
- Expanding Data Assets: Collaborated with various medical institutions to accumulate a database of over 5,000 cases, strengthening model specificity for target cancers such as lung and breast cancer.
Looking Toward 2026: Deepening Clinical Collaboration and Expanding MRD Monitoring
MarkerX is ready to transition our laboratory innovations into real-world clinical environments. We are actively seeking strategic partnerships within the Multiple Myeloma landscape:
- Clinical & Research Partners:We invite oncologists and medical centers to join our clinical studies to validate further applications of relapse monitoring.
- Industrial & Regulatory Partners:We are seeking collaborations for IVD (In Vitro Diagnostic) regulatory strategy, channel distribution, and technology licensing to bring MyeloTrak to the global market.
- Insurance & Healthcare Payers:We aim to integrate precision monitoring into commercial insurance, making high-quality care affordable and accessible.
We sincerely invite all sectors to continue following MarkerX. Together, we will utilize precision medicine to win more time for a better life.